Hypertension, Nocturia, Sleep Disturbance
Conditions
Brief summary
In this study the investigators target three common and comorbid illnesses among older adults namely nocturia or waking at night to void, poor sleep and hypertension. The aim of this proposal is to test behavioral sleep intervention to improve sleep and nocturia vs switching the time of antihypertensive administration to improve nighttime and in turn daytime blood pressure control.
Detailed description
The investigators posit that a vicious cycle operates between nocturia, poor sleep, and nighttime hypertension (HTN). HTN act through the pressure-natriuresis mechanism that links sodium (Na) and BP homeostasis: periodic increases in BP drive compensatory renal excretion of Na (natriuresis) and water (diuresis) to reduce blood volume and BP. Normally, BP and natriuresis declines during sleep, decreasing nighttime urine volume (NUV). Elevated nighttime BP increases nocturnal natriuresis causing an increase in nighttime urine volume and hence, NP: the major etiologic factor for nocturia in the elderly. In a recently completed study (AG050892, PI:Tyagi), it was found that poor sleep blunts the normal nighttime rise in antidiuretic hormone-a potent Na conserving hormone, which leads to nocturnal natriuresis and, as a result, NP. Hence, our model incorporates the effects of poor sleep and nighttime HTN on natriuresis, NP, and nocturia. The investigators postulate that treatments targeted towards these etiologies will help break this vicious cycle. Traditionally, antihypertensive medications are dosed in the morning targeting daytime BP. However, some research suggests that nighttime BP best predicts risk for major cardiovascular events. Several clinical trials of bedtime dosing of BP medication-chronotherapy- show better nighttime BP control. However, no clinical studies have considered or tested chronotherapy as a treatment for nocturia. With respect to poor sleep, the investigators have shown that brief behavioral treatment of insomnia (BBTI) significantly improves not only sleep but also self-reported nocturia among the elderly. Therefore, the investigators envision a multicomponent approach with chronotherapy (bedtime dosing of certain antihypertensives) and behavioral sleep intervention (BBTI) to concurrently address the prevalent and chronic, mutually exacerbating conditions: nocturia, poor sleep, and HTN. The current proposal aims to collect pilot data for a definitive randomized clinical trial. In the proposed pilot study 30 community-dwelling older adults (aged \>65) who take at ≥1 daily non-diuretic antihypertensive medication, have a mean SBP \>135 mm Hg, and awaken ≥2 times nightly to void will be randomly assigned to one of the 3 groups of 10 participants each to 1) morning (am) HTN medication dosing, 2) BBTI with am HTN medication dosing, 3) nighttime non-diuretic HTN medication dosing (chronotherapy) for 6 weeks. At baseline and 6 weeks, participants will undergo 48-hour ambulatory BP monitoring, in-home sleep study, complete a 3-day bladder diary. This protocol will allow the investigators to accomplish following Aims: Aim1: To assess the feasibility and effect of chronotherapy and BBTI in older adults with multiple comorbidities: HTN and nocturia Hypothesis 1: Chronotherapy and BBTI will be (a) feasible treatment options among comorbid older adults, and (b) nocturia and nighttime urine volume, and (c) nighttime systolic blood pressure (SBP) will have a greater decrease in BBTI and chronotherapy groups than usual care. Aim 2: Assess safety and treatment compliance with chronotherapy. Hypothesis 2: The investigators will assess treatment compliance and also collect data on nocturnal lightheadedness and falls to begin to address the safety of HTN chronotherapy.
Interventions
Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
participants will be asked to continue taking their antihypertensive medication within an hour of awakening
Sponsors
Study design
Masking description
The randomization envelopes will be prepared by the study statistician. Randomization and the intervention BBTI will be completed by research nurse and PI and the outcome assessor will be blinded to randomization.
Intervention model description
In the proposed pilot study 30 community-dwelling older adults (aged \>65) who take at ≥1 daily non-diuretic antihypertensive medication, have a mean SBP \>135 mm Hg, and awaken ≥2 times nightly to void will be randomly assigned to one of the 3 groups of 10 participants each to 1) morning (am) HTN medication dosing, 2) BBTI with am HTN medication dosing, 3) nighttime non-diuretic HTN medication dosing (chronotherapy) for 6 weeks.
Eligibility
Inclusion criteria
The study shall include: ambulatory and functionally-independent community-dwelling men and women aged 65+ years, with 1. nocturia ≥2/night, and 2. history of high blood pressure and receives one or more non-diuretic, once daily antihypertensive- angiotensin converting enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), calcium channel blocker (CCB), beta blocker
Exclusion criteria
1. Unstable or acute medical or central nervous system conditions 2. Untreated, current, severe psychiatric condition 3. Untreated, current, severe overactive bladder syndrome 4. Post void residual \> 30ml 5. Montreal cognitive assessment (MOCA) \<26 6. Currently diagnosed and/or treated Obstructive Sleep Apnea, Restless Legs Syndrome, parasomnia 7. Congestive heart failure, by exam 8. Chronic kidney disease, stage III-V (eGFR\<60) 9. \>14 alcohol drinks per week 10. \>3 caffeinated drinks (\ 300mg) per day
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention | Baseline and at 6 weeks | The mean sleep time systolic blood pressure dip will be quantified by calculating the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day value for each participant across the 48-hour recording period comparing baseline and post-intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Nocturia Frequency Pre- vs Post-intervention | Baseline and at 6 weeks | change in nocturia frequency pre- vs post-intervention as determined by 3-day bladder diary completed at both time points |
| Change in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention | Baseline and at 6 weeks | NPi is calculated using nighttime and daytime urine volumes as reported in 3-day bladder diary as follows: NPi=(nocturnal urine volume/24-hour volume)\*100 |
| Change in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention | Baseline and at 6 weeks | PSQI is a self-rated questionnaire for evaluating subjective sleep quality. PSQI global scores range from 0-21, with higher scores indicating worse sleep quality and negative change indicates sleep improvement. |
| Change in Sleep Efficiency Pre- vs Post-intervention | Baseline and at 6 weeks | Sleep efficiency will be calculated as (total sleep time/time in bed)\*100 with time in bed and total sleep times obtained from Zmachine worn by participants pre- and post-intervention |
Countries
United States
Participant flow
Recruitment details
Recruitment started June 2022 through September 2023. The initial screening was completed telephonically and once screened eligible, the interested participants underwent study related assessments and procedures at the study research suite - Continence Research Unit at University of Pittsburgh Medical Center, Montefiore Hospital located in Pittsburgh, Pennsylvania
Pre-assignment details
After the telephone screening, eligible participants were scheduled for the first in-person study visit. No study procedures were performed till informed consent was obtained.
Participants by arm
| Arm | Count |
|---|---|
| AM Antihypertensive Dosing Arm participants will be asked to continue taking their antihypertensive medication within an hour of awakening
AM antihypertensive dosing: participants will be asked to continue taking their antihypertensive medication within an hour of awakening | 10 |
| BBTI Arm participants will receive the behavioral treatment for insomnia BBTI by the study RN. Participants will also be asked to take their antihypertensive medication within an hour of awakening
BBTI: Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia. | 10 |
| PM Antihypertensive Dosing or Chronotherapy Arm participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
PM antihypertensive dosing or Chronotherapy: participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime | 10 |
| Total | 30 |
Baseline characteristics
| Characteristic | Total | AM Antihypertensive Dosing Arm | BBTI Arm | PM Antihypertensive Dosing or Chronotherapy Arm |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 30 Participants | 10 Participants | 10 Participants | 10 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 71.6 years STANDARD_DEVIATION 4.8 | 73.9 years STANDARD_DEVIATION 5 | 69.4 years STANDARD_DEVIATION 4.6 | 71.5 years STANDARD_DEVIATION 4.2 |
| Alpha- blocker | 4 Participants | 2 Participants | 1 Participants | 1 Participants |
| Angiotensin converting enzyme inhibitor/ Angiotensin receptor blocker | 24 Participants | 8 Participants | 9 Participants | 7 Participants |
| Antidepressant | 8 Participants | 1 Participants | 4 Participants | 3 Participants |
| Antimuscarinic | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Beta-blocker | 9 Participants | 3 Participants | 5 Participants | 1 Participants |
| Body mass index (BMI) | 32.2 kg/m2 STANDARD_DEVIATION 6.4 | 31.2 kg/m2 STANDARD_DEVIATION 2.8 | 34 kg/m2 STANDARD_DEVIATION 8.7 | 31.4 kg/m2 STANDARD_DEVIATION 6.5 |
| Calcium channel blocker | 13 Participants | 6 Participants | 3 Participants | 4 Participants |
| Hypnotic | 4 Participants | 0 Participants | 4 Participants | 0 Participants |
| Insulin | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Loop diuretic | 2 Participants | 1 Participants | 1 Participants | 0 Participants |
| Nonsteroidal anti-inflammatory drugs (NSAIDs) | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
| Office diastolic blood pressure | 82 mm Hg STANDARD_DEVIATION 10.5 | 80.4 mm Hg STANDARD_DEVIATION 8.3 | 79.9 mm Hg STANDARD_DEVIATION 11 | 85.7 mm Hg STANDARD_DEVIATION 11.7 |
| Office heart rate | 66.2 beats per minute STANDARD_DEVIATION 10.4 | 66.5 beats per minute STANDARD_DEVIATION 13.4 | 63.6 beats per minute STANDARD_DEVIATION 8.7 | 68.5 beats per minute STANDARD_DEVIATION 8.9 |
| Office systolic blood pressure | 145.8 mm Hg STANDARD_DEVIATION 12.5 | 144.9 mm Hg STANDARD_DEVIATION 13.3 | 137.4 mm Hg STANDARD_DEVIATION 9.5 | 155.5 mm Hg STANDARD_DEVIATION 14.6 |
| oral hypoglycemic | 11 Participants | 3 Participants | 5 Participants | 3 Participants |
| Post void residual | 35.4 ml STANDARD_DEVIATION 63.1 | 47 ml STANDARD_DEVIATION 75.3 | 15.7 ml STANDARD_DEVIATION 11.4 | 18.7 ml STANDARD_DEVIATION 35 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 1 Participants | 3 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 26 Participants | 9 Participants | 7 Participants | 10 Participants |
| Region of Enrollment United States | 30 participants | 10 participants | 10 participants | 10 participants |
| Sex: Female, Male Female | 17 Participants | 4 Participants | 7 Participants | 6 Participants |
| Sex: Female, Male Male | 13 Participants | 6 Participants | 3 Participants | 4 Participants |
| Statin | 19 Participants | 9 Participants | 4 Participants | 6 Participants |
| Thiazide diuretic | 10 Participants | 2 Participants | 3 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 10 | 0 / 10 |
| other Total, other adverse events | 0 / 10 | 0 / 10 | 0 / 10 |
| serious Total, serious adverse events | 0 / 10 | 0 / 10 | 0 / 10 |
Outcome results
Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention
The mean sleep time systolic blood pressure dip will be quantified by calculating the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day value for each participant across the 48-hour recording period comparing baseline and post-intervention
Time frame: Baseline and at 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AM Antihypertensive Dosing Arm | Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention | -0.4 percentage of daytime mean SBP | Standard Deviation 7.9 |
| BBTI Arm | Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention | 7.3 percentage of daytime mean SBP | Standard Deviation 13.5 |
| PM Antihypertensive Dosing or Chronotherapy Arm | Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention | 3.9 percentage of daytime mean SBP | Standard Deviation 10 |
Change in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention
PSQI is a self-rated questionnaire for evaluating subjective sleep quality. PSQI global scores range from 0-21, with higher scores indicating worse sleep quality and negative change indicates sleep improvement.
Time frame: Baseline and at 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AM Antihypertensive Dosing Arm | Change in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention | 0.5 score on a scale | Standard Deviation 2.9 |
| BBTI Arm | Change in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention | -1.4 score on a scale | Standard Deviation 2.2 |
| PM Antihypertensive Dosing or Chronotherapy Arm | Change in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention | -1.2 score on a scale | Standard Deviation 3.7 |
Change in Nocturia Frequency Pre- vs Post-intervention
change in nocturia frequency pre- vs post-intervention as determined by 3-day bladder diary completed at both time points
Time frame: Baseline and at 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AM Antihypertensive Dosing Arm | Change in Nocturia Frequency Pre- vs Post-intervention | -0.3 number of episodes | Standard Deviation 1 |
| BBTI Arm | Change in Nocturia Frequency Pre- vs Post-intervention | -0.6 number of episodes | Standard Deviation 0.7 |
| PM Antihypertensive Dosing or Chronotherapy Arm | Change in Nocturia Frequency Pre- vs Post-intervention | -0.3 number of episodes | Standard Deviation 0.8 |
Change in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention
NPi is calculated using nighttime and daytime urine volumes as reported in 3-day bladder diary as follows: NPi=(nocturnal urine volume/24-hour volume)\*100
Time frame: Baseline and at 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AM Antihypertensive Dosing Arm | Change in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention | 0.5 % of 24h urine output excreted at night | Standard Deviation 7.4 |
| BBTI Arm | Change in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention | -6.0 % of 24h urine output excreted at night | Standard Deviation 9.7 |
| PM Antihypertensive Dosing or Chronotherapy Arm | Change in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention | -0.9 % of 24h urine output excreted at night | Standard Deviation 7.6 |
Change in Sleep Efficiency Pre- vs Post-intervention
Sleep efficiency will be calculated as (total sleep time/time in bed)\*100 with time in bed and total sleep times obtained from Zmachine worn by participants pre- and post-intervention
Time frame: Baseline and at 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AM Antihypertensive Dosing Arm | Change in Sleep Efficiency Pre- vs Post-intervention | -7 %: (total sleep time/time in bed)*100 | Standard Deviation 15.3 |
| BBTI Arm | Change in Sleep Efficiency Pre- vs Post-intervention | 12 %: (total sleep time/time in bed)*100 | Standard Deviation 7.8 |
| PM Antihypertensive Dosing or Chronotherapy Arm | Change in Sleep Efficiency Pre- vs Post-intervention | -3 %: (total sleep time/time in bed)*100 | Standard Deviation 11.8 |